Brief: Firebrick Pharma Says It Got Written Advice From TGA Of Their Decision
07/07/2022 09:27
July 7 (Reuters) - Firebrick Pharma Ltd FRE.AX :
* GOT WRITTEN ADVICE FROM TGA OF THEIR DECISION ON CO'S
REQUEST
* CO HAD REQUESTED RECONSIDERATION OF TGA'S ORIGINAL
DECISION NOT
TO APPROVE NASODINE NASAL SPRAY
* CO INTENDS TO PROCEED TO ADMINISTRATIVE APPEAL TRIBUNAL
* INTENDS TO FILE APPLICATION WITH AAT BY 4 AUGUST
Source text for Eikon: ID:nASX5VRhCD
Further company coverage: FRE.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Firebrick Pharma
See all newsAustralia's Firebrick Pharma jumps on plan to launch Nasodine products in US retail market
Brief: Firebrick Pharma Receives A$293,000 Research And Development Tax Incentive
Brief: Firebrick Pharma Says Nasodine Composition Patent Granted In New Zealand
Brief: Firebrick Pharma Says Nasodine Patent Accepted In Canada
Brief: Firebrick Pharma Secures A$1.5 Million Via Placement